Keep up to date with our latest partnering deals and highlights
Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.
- Monday, 8 December 2014
- AstraZeneca wins three business development awards at 10th Annual Scrip Awards 2014 AstraZeneca won three Scrip Awards at the 10th Annual Scrip Awards 2014, held in London, in the following categories: Best Partnership Alliance, Best Licensing Deal of the Year, and Best Management Team of the Year 2014.
- Tuesday, 16 September 2014
- AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease AstraZeneca and Eli Lilly and Company (Lilly) today announced an agreement to jointly develop and commercialise AZD3293
- Wednesday, 30 July 2014
- AstraZeneca agrees strategic transaction with Almirall in respiratory disease AstraZeneca today announced that it has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones. AstraZeneca has also agreed to make various sales-related payments.